Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory digestive diseases, such as colitis, including e.g. Ulcerative colitis, Crohn's disease, diversion colitis, ischemic colitis, infectious colitis, fulminant colitis, chemical colitis, microscopic colitis, lymphocytic colitis, and atypical colitis, etc.
1. A method of treating Crohn's disease in a mammalian subject, the method comprising administering a pharmaceutical composition to the subject in need of treatment thereof, the composition comprising a c-Jun N-terminal kinase (JNK) specific inhibitor consisting of having an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 11.
2. The method of claim 1 , wherein the JNK inhibitor binds JNK.
3. The method of claim 1 , wherein the JNK inhibitor inhibits the activation of at least one JNK targeted transcription factor when the JNK inhibitor is present in a JNK expressing cell.
4. The method of claim 3 , wherein the JNK targeted transcription factor is selected from the group consisting of c-Jun, ATF2, and Elk1.
5. The method of claim 1 , wherein the JNK inhibitor alters a JNK effect when the peptide is present in a JNK expressing cell.
6. The method of claim 1 , wherein the JNK inhibitor is composed of D-amino acids.
7. The method of claim 1 , wherein the pharmaceutical composition is to be administered by intravenous administration.
8. The method of claim 1 , wherein the JNK inhibitor comprises a JNK binding domain that binds JNK.
9. The method of claim 1 , wherein the JNK inhibitor comprises a JNK binding domain that inhibits the activation of at least one JNK targeted transcription factor when the JNK inhibitor is present in a JNK expressing cell.
10. The method of claim 9 , wherein the JNK targeted transcription factor is selected from the group consisting of c-Jun, ATF2, and Elk1.
11. The method of claim 1 , wherein the JNK inhibitor alters a JNK effect when the amino acid sequence is present in a JNK expressing cell.